This experimental link between p16 and lymphangiogenesis provides a pathobiological concept for earlier clinical observations that associated the loss of p16 with lymph node metastasis in several types of carcinomas (Kawabuchi et al, 1999; Gessner et al, 2002). The gene discussed is CDKN2A; the disease is carcinoma.